- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04238546
Major Adverse Limb Events in Patients With Femoro-popliteal and Below-the-knee Peripheral Arterial Disease Treated With Either Sirolimus-coated Balloon or Standard Uncoated Balloon Angioplasty
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Peripheral artery disease (PAD) is a progressive atherosclerotic disease with symptoms ranging from intermittent claudication (IC) to critical limb ischemia (CLI). The majority of symptomatic PAD patients present with atherosclerotic lesions located in the femoro-popliteal arteries and endovascular therapy is the primary choice if the stenosis/occlusions involve <25 cm of the vessel. A minority of symptomatic PAD patients would present with infra-popliteal (distal or below-the-knee) lesions: in these patients, the endovascular treatment is challenging.
Drug-coated balloons (DCB) and drug-eluting stents (DES) were developed to prevent neo-intimal proliferation and restenosis after percutaneous transluminal angioplasty (PTA), an objective which had been achieved by the local application of either cytostatic (e.g. paclitaxel - a cytoskeletal disruptor) or immunosuppressive (e.g. sirolimus/everolimus - both mTOR inhibitors) substances on the vessel wall.
Over the past decade, a few randomized controlled trials (RCT) compared the efficacy and safety of drug-coated (mainly paclitaxel-coated) devices vs. that of uncoated ones, and demonstrated a significant reduction in restenosis rates, late lumen loss, and incidence of target lesion re-vascularization. However, the size of these trials was often too small to draw firm conclusions concerning major clinical outcomes. Moreover, substantial heterogeneity of the study populations and too restrictive eligibility criteria limited their external validity, leading to a difficult interpretation of the results of later meta-analyses. Indeed, these trials adopted as the primary outcome surrogate (and rather subjective) outcomes, such as vessel patency and target limb re-vascularization, which may be difficult to objectively adjudicate in the setting of an open-label trial, rather than ´hard´ objective clinical endpoints, such as major amputation or urgent revascularization due to critical limb ischemia.
Moreover, despite the short-term effects appeared promising based on imaging outcome, tthe results of a recent meta-analysis of 28 trials showed an increased two-year mortality in the group of patients treated with paclitaxel-coated balloons. Based on these results, and after analysis of follow-up data from the trials that led to the approval of these products, a Food and Drug Administration (FDA) panel concluded that, despite the short-term benefits with paclitaxel-based devices, safety concerns may exist for mid-term mortality risk.
Alternative drug candidates to paclitaxel-coated balloon catheters are the so-called limus-based analogs, which own cytostatic properties and are characterized by a wider therapeutic window. Recently, a novel balloon catheter has been CE-certified: it encapsulates sirolimus in phospholipid drug nanocarriers to improve adhesion properties of sirolimus and to provide better bioavailability. Similarly to paclitaxel-coated and uncoated devices, sirolimus-coated devices are currently approved for routine use in PAD and reimbursed in Switzerland.
The aim of the present trial is to compare the efficacy, as defined by a composite of clinically relevant non-subjective ´hard´ outcomes (major amputation and target lesion re-vascularization for critical limb ischemia), of sirolimus-coated vs. uncoated balloon angioplasty for peripheral artery disease in patients scheduled for infra-inguinal re-vascularization and selected based on a very limited number of inclusion criteria (all comers) aiming at maximization of external validity.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rebecca Spescha, Dr.sc.nat
- Phone Number: 0041432530371
- Email: rebecca.spescha@usz.ch
Study Locations
-
-
-
Fribourg, Switzerland, 1708
- Recruiting
- HFR Fribourg - Hôpital Cantonal / Kantonsspital
-
Contact:
- Rolf Engelberger, PD Dr. med.
- Email: Rolf.Engelberger@h-fr.ch
-
Contact:
- Daniel Périard, Dr. med.
- Email: Daniel.Periard@h-fr.ch
-
Principal Investigator:
- Rolf Engelberger, PD Dr. med.
-
Sub-Investigator:
- Daniel Daniel, Dr. med.
-
Zurich, Switzerland, 8091
- Recruiting
- University Hospital Zurich
-
Contact:
- Nils Kucher, Prof. Dr. med.
- Phone Number: +41442552671
- Email: nils.kucher@usz.ch
-
Contact:
- Stefano Barco, PD Dr. med.
- Email: stefano.barco@usz.ch
-
Principal Investigator:
- Nils Kucher, Prof. Dr. med.
-
Principal Investigator:
- Stefano Barco, PD Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18 years
- Patients requiring endovascular angioplasty for PAD located below the inguinal ligament
- Written informed consent obtained from participant or legal guardian prior to randomization; in patients requiring emergency interventional treatment who are temporarily not capable of providing informed consent, consent will be subsequently obtained after the procedure if strict conditions apply. These include the assessment of the presumed will and patient decree, and requires the allocation of an independent physician
Exclusion Criteria:
- Pregnancy, breastfeeding, or planned pregnancy within the trial period or women of childbearing potential not using an adequate method of contraception
- Patients with known intolerance or allergy to sirolimus
- Participation in this or other clinical trials during the previous 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus-coated group
|
angioplasty with sirolimus-coated balloon catheter
|
Active Comparator: Uncoated group
|
angioplasty with uncoated balloon catheter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
unplanned major amputation of the target limb
Time Frame: one year
|
An unplanned major amputation is defined as any amputation above the ankle on the target limb, which was not planned or not expectable at the time of screening or randomization.
Patients with scheduled amputation undergoing re-vascularization to improve wound healing are referred to as planned amputation and will not count for the primary outcome
|
one year
|
endovascular or surgical target lesion re-vascularization for critical limb ischemia
Time Frame: one year
|
Critical limb ischemia is defined according to a Fontaine stage (classes III-IV)
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
composite of unplanned (major or minor) index-limb amputations or any target lesion re-vascularization within 365 days after enrolment
Time Frame: one year
|
Unplanned major amputation is defined analogously to the definition used for the primary efficacy endpoint
|
one year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death from all causes
Time Frame: up to five years
|
Death from all causes within 30 days, 180 days, one year, two years, and five years
|
up to five years
|
Serious adverse events (SAEs)
Time Frame: one year
|
Serious adverse events (SAEs) during initial hospitalization, within 180 days, and within 365 days
|
one year
|
Serious adverse device related events (SADE)
Time Frame: up to one month
|
Serious adverse device related events (SADE) during initial hospitalization
|
up to one month
|
A composite of all-cause death and MALE
Time Frame: one month
|
A composite of all-cause death and MALE within 30 days
|
one month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nils Kucher, Prof., University of Zurich
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- SirPAD Trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on sirolimus-coated balloon catheter
-
BrosMed Medical Co., LtdChinese Academy of Medical Sciences, Fuwai HospitalNot yet recruiting
-
C. R. BardTerminatedUse and Safety of the LUTONIX® Drug Coated Balloon Catheter in Arteries of the Lower Extremity (LEG)Peripheral Artery DiseaseMalaysia, New Zealand, Canada
-
Acotec Scientific Co., LtdCompleted
-
Acotec Scientific Co., LtdRecruitingPeripheral Artery DiseaseChina
-
Concept Medical Inc.CompletedAtherosclerosis | Peripheral Artery DiseaseSingapore
-
C. R. BardRecruitingArteriovenous FistulaUnited States, Canada
-
C. R. BardCompletedPeripheral Artery DiseaseAustria, Belgium, France, Switzerland, Germany, Italy, Greece, Spain, United Kingdom, Portugal, Saudi Arabia
-
Jena University HospitalConcept Medical Inc.; CoreLab Black Forest; Center for Clinical Studies, University... and other collaboratorsRecruiting
-
JW Medical Systems LtdNot yet recruiting
-
C. R. BardTerminatedPopliteal Artery Stenosis | Popliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery StenosisUnited States